Roche Holding AG (RHHBF)
| Market Cap | 355.04B +33.0% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 23.25 |
| Forward PE | 17.23 |
| Dividend | 12.41 (2.73%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 3 |
| Open | 453.84 |
| Previous Close | 444.96 |
| Day's Range | 453.84 - 453.84 |
| 52-Week Range | 301.27 - 514.08 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
Swiss drugmaker Roche said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5% of their b...
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial
The results for enicepatide reinforce the company's ambitions to rapidly develop its portfolio of medicines for people with obesity, diabetes and cardiovascular disease.
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today announced positive topline results from CT-388-104, a Phase II clini...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
Basel, 22 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, o...
European Commission approves Roche's Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
Basel, 21 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for the treatment of neo...
CHMP recommends EU approval of Roche's Ocrevus for children and adolescents with relapsing multiple sclerosis
Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the appro...
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today celebrated the grand opening of the Roche Genentech Innovation Cente...
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the grand opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech's US research presence in...
Roche's Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/...
Genentech's Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the Phase III CELESTIMO study evaluating Lunsumio® (mosunetuzuma...
Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Basel, 13 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Pel...
U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FDA filing acceptance announced for Enspryng (satralizumab) in MOGAD, a rare neurological disease.
U.S. FDA grants Priority Review for Roche's Enspryng for MOGAD, an autoimmune disease with no approved treatments
Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Applicati...
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies
WATERTOWN, Mass.--(BUSINESS WIRE)--Treeline Biosciences, Inc. (“Treeline”) today announced a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-1...
Roche signs global licensing pact for Simcere's experimental blood cancer drug
Switzerland's Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma. Differential diagnosis...
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55, Roche said on Monday m...
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
INDIANAPOLIS, Aug. 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau...
Roche's US subsidiary Genentech announces manufacturing expansion in the United States
Basel, 20 August 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY) today announced plans to invest approximately $750 million in a new device fill-finish manufacturing facilit...
Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today announced plans to invest approximately $750 million in a new device...
Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Spr...
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and suppor...